(Q38064058)

28 August 2017

1 reference

title

New technologies and procedures for cervical cancer screening (English)

1 reference

28 August 2017

main subject

cervix uterine cancer

1 reference

10

Anne Szarewski

1 reference

Magnus von Knebel Doeberitz

28 August 2017

3

object named as

Magnus von Knebel Doeberitz

1 reference

Rengaswamy Sankaranarayanan

28 August 2017

8

object named as

Rengaswamy Sankaranarayanan

1 reference

28 August 2017

1

Jack Cuzick

1 reference

28 August 2017

9

Peter J F Snijders

1 reference

28 August 2017

7

Chris J L M Meijer

1 reference

28 August 2017

Christine Bergeron

2

1 reference

28 August 2017

Patti Gravitt

4

1 reference

28 August 2017

Jose Jeronimo

5

1 reference

28 August 2017

Attila T Lorincz

6

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 November 2012

1 reference

28 August 2017

1 reference

28 August 2017

volume

30 Suppl 5

1 reference

28 August 2017

page(s)

F107-16

1 reference

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Subsequent risks for cervical precancer and cancer in women with low-grade squamous intraepithelial lesions unconfirmed by colposcopy-directed biopsy: results from a multicenter, prospective, cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

The ATHENA human papillomavirus study: design, methods, and baseline results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Evaluation of HPV-16 and HPV-18 Genotyping for the Triage of Women With High-Risk HPV+ Cytology-Negative Results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

p16(INK4a) immunostaining as an alternative to histology review for reliable grading of cervical intraepithelial lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Impact of utilizing p16INK4A immunohistochemistry on estimated performance of three cervical cancer screening tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

p16 ink4a and HPV L1 immunohistochemistry is helpful for estimating the behavior of low-grade dysplastic lesions of the cervix uteri.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Biomarker expression in cervical intraepithelial neoplasia: potential progression predictive factors for low-grade lesions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

The sensitivity and specificity of p16(INK4a) cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL pap cytology results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Evaluation of p16INK4a, minichromosome maintenance protein 2, DNA topoisomerase IIalpha, ProEx C, and p16INK4a/ProEx C in cervical squamous intraepithelial lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

p16, Ki-67, and BD ProExC immunostaining: a practical approach for diagnosis of cervical intraepithelial neoplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

BD-ProExC as Adjunct Molecular Marker for Improved Detection of CIN2+ after HPV Primary Screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid-based cytology samples from uterine cervical lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

DNA methylation and human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

The Promise and the Problems of Epigenetics Biomarkers in Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Epigenetic predictor of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Detection of cervical neoplasia by DNA methylation analysis in cervico-vaginal lavages, a feasibility study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Quantitative DNA methylation analysis detects cervical intraepithelial neoplasms type 3 and worse.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Distinct human papillomavirus type 16 methylomes in cervical cells at different stages of premalignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Methylation of the human papillomavirus-18 L1 gene: a biomarker of neoplastic progression?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

A higher degree of methylation of the HPV 16 E6 gene is associated with a lower likelihood of being diagnosed with cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Epidemiologic classification of human papillomavirus types associated with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Molecular biology of human papillomavirus infection and cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Feasibility study of a human papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Acceptability of unsupervised HPV self-sampling using written instructions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Exploring the acceptability of two self-sampling devices for human papillomavirus testing in the cervical screening context: a qualitative study of Muslim women in London

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Looking ahead: a case for human papillomavirus testing of self-sampled vaginal specimens as a cervical cancer screening strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Self-sampling of vaginal fluid and high-risk human papillomavirus testing in women aged 50 years or older not attending Papanicolaou smear screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Improved sensitivity of vaginal self-collection and high-risk human papillomavirus testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Barriers to cervical cancer screening attendance in England: a population-based survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Self-sampling of the vaginal fluid at home combined with high-risk HPV testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Self-sampling and HPV testing or ordinary Pap-smear in women not regularly attending screening: a randomised study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

HPV self-sampling as an alternative strategy in non-attenders for cervical screening - a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

The effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: a randomised controlled trial (ISRCTN96071600)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Comparative community outreach to increase cervical cancer screening in the Mississippi Delta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Training for cervical cancer prevention programs in low-resource settings: focus on visual inspection with acetic acid and cryotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Accuracy of visual inspection with acetic acid for cervical cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

The role of low-level magnification in visual inspection with acetic acid for the early detection of cervical neoplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

HPV screening for cervical cancer in rural India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Cost-effectiveness of cervical-cancer screening in five developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Screening for cervical neoplasia in Bangladesh using visual inspection with acetic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Can visual cervical screening be sustained in routine health services? Experience from Mali, Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Visual inspection methods for cervical cancer prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Cervical cancer screening with naked-eye visual inspection in Colombia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Accuracy of visual screening for cervical neoplasia: Results from an IARC multicentre study in India and Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Visual inspection as a cervical cancer screening method in a primary health care setting in Africa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

Analysis of the effectiveness of visual inspection with acetic acid/Lugol's iodine in one-time and annual follow-up screening in rural China.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.088

10.1016/J.VACCINE.2012.05.088

7 January 2021

Identifiers

DOI

1 reference

28 August 2017

1 reference